<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Elisence – Phase 6: Global Medication Brain</title>

    <!-- Elisa chat widget script -->
    <script defer src="elisa-chat.js"></script>

    <style>
        :root {
            --bg-space: radial-gradient(circle at top, #04101f 0%, #020617 45%, #000000 100%);
            --text-main: #e8f4fc;
            --text-soft: #cbd5f5;
            --text-muted: #94a3b8;
            --accent: #38bdf8;
            --accent-soft: #7dd3fc;
            --card-bg: rgba(15, 23, 42, 0.96);
            --card-border: rgba(56, 189, 248, 0.9);
            --shadow-strong: 0 0 28px rgba(56, 189, 248, 0.9), 0 0 52px rgba(15, 23, 42, 0.9);
        }

        * {
            box-sizing: border-box;
        }

        body {
            margin: 0;
            min-height: 100vh;
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Arial, Helvetica, sans-serif;
            background: var(--bg-space);
            color: var(--text-main);
        }

        /* Top dot + label */
        .top-dot {
            position: fixed;
            left: 16px;
            top: 16px;
            width: 11px;
            height: 11px;
            border-radius: 999px;
            background: #38bdf8;
            box-shadow: 0 0 14px rgba(56, 189, 248, 0.9);
            z-index: 900;
        }

        .top-dot-label {
            position: fixed;
            left: 36px;
            top: 11px;
            padding: 6px 10px;
            border-radius: 999px;
            border: 1px solid rgba(148, 163, 184, 0.6);
            background: rgba(15, 23, 42, 0.9);
            font-size: 0.7rem;
            letter-spacing: 0.18em;
            text-transform: uppercase;
            color: #e5f2ff;
            z-index: 900;
        }

        /* Side navigation (pills) */
        .side-nav {
            position: fixed;
            right: 32px;
            top: 50%;
            transform: translateY(-50%);
            display: flex;
            flex-direction: column;
            gap: 12px;
            z-index: 950;
        }

        .nav-btn {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            padding: 0.65rem 1.5rem;
            border-radius: 999px;
            border: 1px solid rgba(148, 163, 184, 0.75);
            background: radial-gradient(circle at top left, rgba(56, 189, 248, 0.2), rgba(15, 23, 42, 0.96));
            color: #e2e8f0;
            font-size: 0.78rem;
            letter-spacing: 0.16em;
            text-transform: uppercase;
            text-decoration: none;
            box-shadow: 0 0 14px rgba(15, 23, 42, 0.9);
            backdrop-filter: blur(12px);
            transition: transform 0.16s ease, box-shadow 0.16s ease, border-color 0.16s ease, background 0.16s ease;
        }

        .nav-btn:hover {
            transform: translateX(-2px);
            border-color: rgba(56, 189, 248, 0.95);
            box-shadow: 0 0 20px rgba(56, 189, 248, 0.9);
            background: radial-gradient(circle at top left, rgba(56, 189, 248, 0.35), rgba(15, 23, 42, 0.98));
        }

        .nav-btn:active {
            transform: translateX(-1px) translateY(1px) scale(0.99);
        }

        /* Layout wrapper */
        .page-wrapper {
            max-width: 1200px;
            margin: 0 auto;
            padding: 96px 1.8rem 72px 1.8rem;
        }

        .hero-area {
            margin-bottom: 2.4rem;
        }

        .phase-hero-card {
            background: radial-gradient(circle at top left, rgba(56, 189, 248, 0.28), rgba(15, 23, 42, 0.98));
            border-radius: 26px;
            border: 1px solid var(--card-border);
            box-shadow: var(--shadow-strong);
            padding: 1.6rem 1.8rem;
        }

        .phase-hero-inner {
            display: flex;
            gap: 1.8rem;
            align-items: stretch;
        }

        .phase-hero-logo-box {
            flex: 0 0 290px;
            border-radius: 22px;
            background: radial-gradient(circle at top, #0b1220, #020617);
            display: flex;
            align-items: center;
            justify-content: center;
            padding: 0.75rem;
            box-shadow: 0 0 24px rgba(15, 23, 42, 0.9), 0 0 40px rgba(15, 23, 42, 0.9);
        }

        .phase-hero-logo {
            width: 100%;
            max-width: 360px;
            height: auto;
            border-radius: 18px;
            box-shadow: 0 0 28px rgba(15, 23, 42, 0.95);
        }

        .phase-hero-text-box {
            flex: 1;
            display: flex;
            flex-direction: column;
            justify-content: center;
        }

        .phase-label {
            font-size: 0.78rem;
            text-transform: uppercase;
            letter-spacing: 0.18em;
            color: var(--text-muted);
            margin-bottom: 0.3rem;
        }

        .phase-title {
            font-size: 1.9rem;
            letter-spacing: 0.06em;
            text-transform: uppercase;
            color: #f9fafb;
            margin: 0 0 0.35rem 0;
        }

        .phase-subtitle {
            font-size: 0.95rem;
            letter-spacing: 0.14em;
            text-transform: uppercase;
            color: #93c5fd;
            margin-bottom: 0.6rem;
        }

        .phase-lead {
            font-size: 0.98rem;
            color: var(--text-soft);
            margin-bottom: 0.7rem;
        }

        .phase-hero-bullets {
            margin: 0.3rem 0 0 0;
            padding-left: 1.1rem;
            font-size: 0.9rem;
            color: #dbeafe;
        }

        .phase-hero-bullets li {
            margin-bottom: 0.2rem;
        }

        /* Phase detail cards */
        .phase-main {
            max-width: 1100px;
            margin: 0 auto;
        }

        .info-card {
            background: var(--card-bg);
            border-radius: 20px;
            border: 1px solid var(--card-border);
            box-shadow: var(--shadow-strong);
            padding: 1.8rem 1.7rem;
            margin-bottom: 1.8rem;
        }

        .info-card h2 {
            margin-top: 0;
            margin-bottom: 0.85rem;
            font-size: 1.3rem;
            color: var(--accent-soft);
        }

        .info-card h3 {
            margin-top: 1.1rem;
            margin-bottom: 0.4rem;
            font-size: 1.02rem;
            color: #bae6fd;
        }

        .info-card p {
            margin: 0.35rem 0;
            font-size: 0.94rem;
            color: #e5f2ff;
        }

        .info-card ul {
            margin: 0.45rem 0 0.25rem 1.2rem;
            padding-left: 0.3rem;
        }

        .info-card li {
            margin-bottom: 0.32rem;
            font-size: 0.93rem;
        }

        .tagline {
            font-size: 0.94rem;
            color: #93c5fd;
            margin-bottom: 0.45rem;
        }

        .subtle {
            font-size: 0.88rem;
            color: var(--text-muted);
        }

        /* Responsive */
        @media (max-width: 900px) {
            .page-wrapper {
                padding: 80px 1.2rem 80px 1.2rem;
            }

            .phase-hero-inner {
                flex-direction: column;
            }

            .phase-hero-logo-box {
                flex: 0 0 auto;
            }

            .side-nav {
                right: 50%;
                bottom: 18px;
                top: auto;
                transform: translateX(50%);
                flex-direction: row;
                flex-wrap: wrap;
                justify-content: center;
                gap: 10px;
            }

            .nav-btn {
                font-size: 0.7rem;
                padding: 0.6rem 1.1rem;
            }

            .info-card {
                padding: 1.5rem 1.35rem;
            }
        }
    </style>
</head>
<body>

<div class="top-dot"></div>
<div class="top-dot-label">ELISENCE</div>

<nav class="side-nav">
    <a class="nav-btn" href="index.html">Home</a>
    <a class="nav-btn" href="index.html#phases">Phases</a>
    <a class="nav-btn" href="about.html">About</a>
    <a class="nav-btn" href="story.html">Story</a>
    <a class="nav-btn" href="video.html">Videos</a>
    <a class="nav-btn" href="contact.html">Contact</a>
</nav>

<div class="page-wrapper">
    <!-- HERO -->
    <section class="hero-area">
        <div class="phase-hero-card">
            <div class="phase-hero-inner">
                <div class="phase-hero-logo-box">
                    <img src="elisence.png"
                         alt="Elisence – Global Digital Health & Humanity Platform"
                         class="phase-hero-logo">
                </div>
                <div class="phase-hero-text-box">
                    <div class="phase-label">PHASE 6</div>
                    <h1 class="phase-title">Global Medication Brain</h1>
                    <div class="phase-subtitle">
                        MULTILINGUAL · ZERO-TRUST · JURISDICTION-AWARE
                    </div>
                    <p class="phase-lead">
                        Phase 6 is the multilingual, jurisdiction-aware, zero-trust
                        <strong>Global Medication Brain</strong> of Elisence. It safely understands and
                        structures medication behaviour across five languages and powers every major phase of
                        the platform while staying aligned with NHS, FDA, EU MDR, and GCC regulations.
                    </p>
                    <ul class="phase-hero-bullets">
                        <li>Understands free-text and voice-transcribed medication sentences.</li>
                        <li>Converts them into safe, auditable medication events.</li>
                        <li>Acts as the single medication source of truth across Elisence.</li>
                    </ul>
                </div>
            </div>
        </div>
    </section>

    <!-- DETAIL CARDS -->
    <main class="phase-main">

        <!-- 1. WHAT PHASE 6 REALLY IS -->
        <section class="info-card">
            <h2>1. What Phase 6 Really Is (Honest, Precise)</h2>
            <p>
                Phase 6 is the “Global Medication Brain” of Elisence.
                It is not a medical diagnosis engine and not a drug-recommendation system.
                It is a strictly controlled, zero-trust semantic engine that
                <strong>understands</strong>, <strong>structures</strong>, and
                <strong>sanity-checks</strong> anything users say or type about medications.
            </p>
            <p>
                This phase converts natural human language (text or voice-transcribed speech)
                into a <strong>safe, structured medication event</strong> that downstream systems can trust.
            </p>
            <p>
                It is already fully built as a stable baseline, and is now evolving into a global
                drug-intelligence layer that will power:
            </p>
            <ul>
                <li>Diabetes</li>
                <li>Weight-Loss (GLP-1)</li>
                <li>Women+ Health</li>
                <li>AHE (Advanced Health Engine)</li>
                <li>Voice / Zero-Typing (Phase 13)</li>
                <li>Blind-Assist / Accessibility modules</li>
                <li>Clinician dashboards (future)</li>
            </ul>
        </section>

        <!-- 2. WHAT IS ALREADY BUILT -->
        <section class="info-card">
            <h2>2. What Is Already Built (Verifiable Today)</h2>
            <p>
                The current engine in Phase 6 is a real, working baseline. It includes:
            </p>

            <h3>2.1 Multilingual Input Normalization</h3>
            <ul>
                <li>Works in <strong>EN, FA, AR, TR, RO</strong>.</li>
                <li>Cleans text, fixes spacing, unifies digits, normalises casing.</li>
                <li>Prepares tokens for downstream parsing.</li>
            </ul>
            <p class="subtle">Implemented &amp; tested — screenshots, code &amp; logs available.</p>

            <h3>2.2 Spell-Correction &amp; Token Normalization</h3>
            <ul>
                <li>Advanced dictionaries for drug names (e.g., “monjaro”, “mounjaru” → “Mounjaro”).</li>
                <li>Correction of daily language mistakes across 5 languages.</li>
            </ul>
            <p class="subtle">Implemented — in code.</p>

            <h3>2.3 Drug Detection (Deterministic)</h3>
            <ul>
                <li>Recognises Mounjaro, Ozempic, Wegovy, Metformin and other GLP-1 / diabetes medications.</li>
                <li>No hallucination; either a clear detection or <code>"no_match"</code>.</li>
            </ul>
            <p class="subtle">Implemented — in code.</p>

            <h3>2.4 Action Detection (take / stop / miss)</h3>
            <ul>
                <li>Multilingual intent engine with per-language lexicons.</li>
                <li>Negation detection (e.g., “نزنم”, “لا”, “don’t”).</li>
                <li>Fully deterministic, no LLM involved.</li>
            </ul>
            <p class="subtle">Implemented — in code.</p>

            <h3>2.5 Dose Parsing</h3>
            <ul>
                <li>Regex-based dose extraction (2.5mg, 5 mg, “دو و نیم میلی‌گرم”).</li>
                <li>Unit normalisation (“mg” unified across languages).</li>
            </ul>
            <p class="subtle">Implemented — in code.</p>

            <h3>2.6 Date Recognition</h3>
            <ul>
                <li>Recognises ISO dates, UK style, and numeric strings (YYYYMMDD).</li>
                <li>Rejects ambiguous dates under zero-trust rules.</li>
            </ul>
            <p class="subtle">Implemented — in code.</p>

            <h3>2.7 Semantic Medication Event</h3>
            <p>
                Everything above is combined into a structured object:
            </p>
            <ul>
                <li>drug_name</li>
                <li>action</li>
                <li>dose</li>
                <li>date_iso</li>
                <li>warnings</li>
                <li>confidence</li>
                <li>uncertainty_reason</li>
                <li>audit / debug fields</li>
            </ul>
            <p class="subtle">
                This semantic event backbone is already integrated as a core part of Elisence.
            </p>

            <h3>2.8 Phase-Wide API (<code>smart_understand</code>)</h3>
            <ul>
                <li>The unified endpoint for all phases.</li>
                <li>Used by Phase 5 (Elisa), Phase 13 (Voice), Phase 8 (AHE), Diabetes, GLP-1, Women+.</li>
            </ul>
            <p class="subtle">
                Implemented as a stable, single source of truth for medication understanding.
            </p>
        </section>

        <!-- 3. ROADMAP -->
        <section class="info-card">
            <h2>3. What Phase 6 Will Become (Realistic Roadmap)</h2>
            <p>
                Phase 6 is on track to evolve into a global medication intelligence engine.
            </p>

            <h3>3.1 Ontology v1.0 (Next Step)</h3>
            <p>
                Introduction of a controlled drug-ontology with fields:
            </p>
            <ul>
                <li>drug_id, class, mechanism</li>
                <li>adult dose ranges</li>
                <li>regulatory categories (UK/EU/GCC)</li>
                <li>availability per country</li>
                <li>safety notes (never shown directly to users)</li>
            </ul>
            <p>
                This will make Elisence independent from proprietary drug databases used by Omada,
                Livongo, and Huma.
            </p>

            <h3>3.2 Sanity-Check Layer</h3>
            <p>
                Non-diagnostic rules to detect:
            </p>
            <ul>
                <li>unrealistic doses (e.g., “50 mg Mounjaro”).</li>
                <li>impossible frequencies.</li>
                <li>contradictory statements.</li>
            </ul>
            <p>
                Output is always safe and conservative:
                <br>
                → “Please review with a clinician.”
            </p>

            <h3>3.3 Candidate Drug Learning (Supervised Learning)</h3>
            <ul>
                <li>System detects unknown drug names mentioned repeatedly.</li>
                <li>Stores them as candidates for clinical review.</li>
                <li>Requires human clinical approval before activation.</li>
            </ul>
            <p class="subtle">Zero-Trust and BBVP-compliant.</p>

            <h3>3.4 Global Class Mapping</h3>
            <p>
                Mapping each drug to:
            </p>
            <ul>
                <li>GLP-1 class</li>
                <li>SGLT2</li>
                <li>Insulins</li>
                <li>Obesity pharmacotherapy</li>
            </ul>
            <p class="subtle">
                General, non-diagnostic information only.
            </p>

            <h3>3.5 Multi-Phase Integration</h3>
            <p>
                Phase 6 becomes the single medication source of truth for:
            </p>
            <ul>
                <li>Weight / GLP-1 engine (Phase 3)</li>
                <li>Women+ (Phase 7)</li>
                <li>Diabetes &amp; AHE (Phase 8)</li>
                <li>Personality &amp; Voice (Phase 5 &amp; 13)</li>
                <li>Accessibility &amp; Blind-Assist.</li>
            </ul>

            <h3>3.6 Cross-Market Regulatory Alignment</h3>
            <ul>
                <li>Non-Device CDS (FDA).</li>
                <li>Wellness / information layer (EU MDR).</li>
                <li>DCB0129 / 0160 risk controls (NHS).</li>
                <li>PDPL / Qatar / GCC residency support.</li>
            </ul>
            <p>
                This ensures minimal regulatory friction and maximum safety.
            </p>
        </section>

        <!-- 4. LEGAL SAFETY -->
        <section class="info-card">
            <h2>4. Why This Phase Is Legally Safe</h2>
            <p>
                Phase 6 is intentionally designed <strong>not</strong> to cross into diagnosis or treatment.
            </p>

            <h3>4.1 NHS</h3>
            <ul>
                <li>Classified as a Health IT component.</li>
                <li>No clinical decision-making.</li>
                <li>Outputs are informational only.</li>
                <li>Every inference is auditable.</li>
                <li>Hazard log is maintained.</li>
            </ul>

            <h3>4.2 FDA</h3>
            <ul>
                <li>Falls under “Non-Device Clinical Decision Support”.</li>
                <li>User (clinician or patient) can independently evaluate the basis of the output.</li>
                <li>No automated treatment recommendations.</li>
            </ul>

            <h3>4.3 EU MDR</h3>
            <ul>
                <li>No standalone medical purpose.</li>
                <li>Does not directly influence treatment decisions.</li>
                <li>A future professional module can be isolated with its own MDR class.</li>
            </ul>

            <h3>4.4 GCC</h3>
            <ul>
                <li>Data residency supported.</li>
                <li>Strong PDPL alignment.</li>
                <li>Non-diagnostic layer → no medical licensing required.</li>
            </ul>

            <h3>4.5 Zero-Trust</h3>
            <ul>
                <li>Every input is treated as untrusted.</li>
                <li>Low-confidence cases trigger clarification.</li>
                <li>Never “guess” a drug or dose.</li>
                <li>No silent assumptions.</li>
            </ul>

            <h3>4.6 BBVP (Build-Back-Verify-Prove)</h3>
            <ul>
                <li><strong>Build</strong> – implement the feature.</li>
                <li><strong>Back</strong> – create a rollback plan.</li>
                <li><strong>Verify</strong> – tests, accuracy checks, fuzzing.</li>
                <li><strong>Prove</strong> – evidence pack with SHA-256 hashes.</li>
            </ul>
            <p>
                This is what makes Phase 6 regulator-ready.
            </p>
        </section>

        <!-- 5. VOICE SUPPORT -->
        <section class="info-card">
            <h2>5. How Phase 6 Supports Voice (Phase 13)</h2>
            <p>
                Phase 13 handles speech-to-text and high-level intent classification.
                Phase 6 interprets the medication content.
            </p>

            <p>
                Together they enable:
            </p>
            <ul>
                <li>“Elisa, I forgot my dose”.</li>
                <li>“الیسا دیشب داروم رو نزدم”.</li>
                <li>“Elisa, increase to 5 mg next week?” → flagged for clinical confirmation.</li>
            </ul>

            <p>
                Noise handling:
            </p>
            <ul>
                <li>Phase 13 provides an STT confidence score.</li>
                <li>If confidence &lt; threshold → Phase 6 asks for confirmation.</li>
                <li>No uncontrolled interpretations (Zero-Trust preserved).</li>
            </ul>
        </section>

        <!-- 6. INVESTOR VALUE -->
        <section class="info-card">
            <h2>6. Why This Phase Is Attractive for Investors</h2>
            <p>
                This is a realistic, infrastructure-focused value proposition — not hype.
            </p>

            <h3>6.1 Solves a Real Global Problem</h3>
            <p>
                Understanding medication behaviour across languages and contexts is extremely hard and
                expensive. Phase 6 addresses this gap directly.
            </p>

            <h3>6.2 Competes With &amp; Exceeds Omada / Livongo / Huma in One Area</h3>
            <p>
                Most existing platforms focus on:
            </p>
            <ul>
                <li>English-only (mostly US).</li>
                <li>Structured inputs.</li>
                <li>Nurse-led interpretation.</li>
            </ul>
            <p>
                Elisence offers:
            </p>
            <ul>
                <li>Five languages from day one.</li>
                <li>Zero-typing voice support.</li>
                <li>Automatic structuring of free-text.</li>
                <li>Jurisdiction-aware behaviour.</li>
                <li>BBVP + Zero-Trust medication intelligence.</li>
            </ul>
            <p>
                No competitor has all of these combined in a single engine.
            </p>

            <h3>6.3 Safe for Regulators</h3>
            <ul>
                <li>Not a medical device.</li>
                <li>Not diagnosis.</li>
                <li>Not direct medical advice.</li>
                <li>Only structured understanding → very low legal risk.</li>
            </ul>

            <h3>6.4 Essential for Future Phases</h3>
            <p>
                Phase 6 is the foundation for the drug-related intelligence powering:
            </p>
            <ul>
                <li>AHE risk models.</li>
                <li>GLP-1 / obesity routes.</li>
                <li>Women+ medication cross-checking.</li>
                <li>Voice accessibility for blind users.</li>
                <li>Government dashboards and research tools (future).</li>
            </ul>
            <p>
                Investors understand core infrastructure value.
            </p>
        </section>

        <!-- 7. LIMITATIONS -->
        <section class="info-card">
            <h2>7. Limitations (Honest &amp; Transparent)</h2>
            <p>
                Phase 6 does <strong>not</strong> currently:
            </p>
            <ul>
                <li>Classify all global drugs.</li>
                <li>Handle all dialects in Arabic or Persian.</li>
                <li>Detect drug–drug interactions.</li>
                <li>Perform medical triage.</li>
                <li>Provide automated dosing suggestions.</li>
                <li>Replace clinicians.</li>
            </ul>
            <p>
                These are intentionally excluded to avoid:
            </p>
            <ul>
                <li>High-risk MDR / FDA classification.</li>
                <li>Clinical liability.</li>
                <li>Unsafe or overreaching behaviour.</li>
            </ul>
        </section>

        <!-- 8. SUMMARY -->
        <section class="info-card">
            <h2>8. One-Sentence Summary</h2>
            <p>
                Phase 6 is the multilingual, jurisdiction-aware, zero-trust
                <strong>Global Medication Brain</strong> of Elisence — a safe, auditable foundation that
                understands and structures medication behaviour across five languages, powers every major phase
                of the platform, and remains legally compliant across NHS, FDA, EU, and GCC markets.
            </p>
        </section>

    </main>
</div>

<!-- Elisa chat widget root -->
<div id="elisa-chat-root"></div>

</body>
</html>
